126 related articles for article (PubMed ID: 27020604)
1. Development of oral self nano-emulsifying delivery system(s) of lanreotide with improved stability against presystemic thiol-disulfide exchange reactions.
Ijaz M; Bonengel S; Zupančič O; Yaqoob M; Hartl M; Hussain S; Huck CW; Bernkop-Schnürch A
Expert Opin Drug Deliv; 2016 Jul; 13(7):923-9. PubMed ID: 27020604
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the protective effect of self-emulsifying peptide drug delivery systems towards intestinal proteases and glutathione.
Hetényi G; Griesser J; Moser M; Demarne F; Jannin V; Bernkop-Schnürch A
Int J Pharm; 2017 May; 523(1):357-365. PubMed ID: 28347848
[TBL] [Abstract][Full Text] [Related]
3. Thiol-Disulfide Exchange in Human Growth Hormone.
Chandrasekhar S; Moorthy BS; Xie R; Topp EM
Pharm Res; 2016 Jun; 33(6):1370-82. PubMed ID: 26887678
[TBL] [Abstract][Full Text] [Related]
4. Kinetics and Equilibria of the Thiol/Disulfide Exchange Reactions of Somatostatin with Glutathione.
Rabenstein DL; Weaver KH
J Org Chem; 1996 Oct; 61(21):7391-7397. PubMed ID: 11667665
[TBL] [Abstract][Full Text] [Related]
5. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
[TBL] [Abstract][Full Text] [Related]
6. Development and in vitro evaluation of an oral SEDDS for desmopressin.
Zupančič O; Leonaviciute G; Lam HT; Partenhauser A; Podričnik S; Bernkop-Schnürch A
Drug Deliv; 2016 Jul; 23(6):2074-83. PubMed ID: 26923905
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
Colao A; Marzullo P; Ferone D; Marinò V; Pivonello R; Di Somma C; Di Sarno A; Giaccio A; Lombardi G
J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136
[TBL] [Abstract][Full Text] [Related]
8. Electronic and vibrational spectra of novel Lanreotide peptide capped gold nanoparticles.
Molina-Trinidad EM; Estévez-Hernández O; Rendón L; Garibay-Febles V; Reguera E
Spectrochim Acta A Mol Biomol Spectrosc; 2011 Nov; 82(1):283-9. PubMed ID: 21820948
[TBL] [Abstract][Full Text] [Related]
9. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
Baldelli R; Colao A; Razzore P; Jaffrain-Rea ML; Marzullo P; Ciccarelli E; Ferretti E; Ferone D; Gaia D; Camanni F; Lombardi G; Tamburrano G
J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
[TBL] [Abstract][Full Text] [Related]
10. Biscysteine-Bearing Peptide Probes To Reveal Extracellular Thiol-Disulfide Exchange Reactions Promoting Cellular Uptake.
Li T; Gao W; Liang J; Zha M; Chen Y; Zhao Y; Wu C
Anal Chem; 2017 Aug; 89(16):8501-8508. PubMed ID: 28714307
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of lanreotide Autogel
Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
[TBL] [Abstract][Full Text] [Related]
12. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
13. Disulfide-Mediated Bioconjugation: Disulfide Formation and Restructuring on the Surface of Nanomanufactured (Microfluidics) Nanoparticles.
Geven M; Luo H; Koo D; Panambur G; Donno R; Gennari A; Marotta R; Grimaldi B; Tirelli N
ACS Appl Mater Interfaces; 2019 Jul; 11(30):26607-26618. PubMed ID: 31282644
[TBL] [Abstract][Full Text] [Related]
14. Dehydroascorbic acid S-Thiolation of peptides and proteins: Role of homocysteine and glutathione.
Ahuié Kouakou G; Gagnon H; Lacasse V; Wagner JR; Naylor S; Klarskov K
Free Radic Biol Med; 2019 Sep; 141():233-243. PubMed ID: 31228548
[TBL] [Abstract][Full Text] [Related]
15. Stability and structure-forming properties of the two disulfide bonds of alpha-conotoxin GI.
Kaerner A; Rabenstein DL
Biochemistry; 1999 Apr; 38(17):5459-70. PubMed ID: 10220333
[TBL] [Abstract][Full Text] [Related]
16. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism.
Corda H; Kummer S; Welters A; Teig N; Klee D; Mayatepek E; Meissner T
Orphanet J Rare Dis; 2017 Jun; 12(1):108. PubMed ID: 28576129
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.
Temmerman F; Gevers T; Ho TA; Vanslembrouck R; Coudyzer W; van Pelt J; Bammens B; Pirson Y; Drenth JP; Nevens F
Aliment Pharmacol Ther; 2013 Aug; 38(4):397-406. PubMed ID: 23799922
[TBL] [Abstract][Full Text] [Related]
18. Oral peptide delivery: are there remarkable effects on drugs through sulfhydryl conjugation?
Huck CW; Pezzei V; Schmitz T; Bonn GK; Bernkop-Schnürch A
J Drug Target; 2006 Apr; 14(3):117-25. PubMed ID: 16753825
[TBL] [Abstract][Full Text] [Related]
19. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.
Schopohl J; Strasburger CJ; Caird D; Badenhoop K; Beuschlein F; Droste M; Plöckinger U; Petersenn S;
Exp Clin Endocrinol Diabetes; 2011 Mar; 119(3):156-62. PubMed ID: 21086246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
